MedTrace Logo

Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate

NCT01454791 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-03-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the effect of Diclofenac Sodium Topical Gel (DSTG) on injection site reaction following self-administer glatiramer acetate in people with Multiple Sclerosis.

Conditions

Interventions

DRUG

diclofenac sodium topical gel

diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo

OTHER

Placebo

a placebo gel is applied 1-4 times per day for two weeks.

Sponsors & Collaborators

  • Teva Neuroscience, Inc.

    collaborator INDUSTRY

  • Brown, Theodore R., M.D., MPH

    lead INDIV

Principal Investigators

  • Ted R Brown, MD, MPH · MS Center at Evergreen Healthcare

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01454791 on ClinicalTrials.gov